Literature DB >> 26601852

An outbreak of high-level azithromycin resistant Neisseria gonorrhoeae in England.

Stephanie A Chisholm1, Janet Wilson2, Sarah Alexander1, Francesco Tripodo1, Ali Al-Shahib3, Ulf Schaefer3, Kieren Lythgow3, Helen Fifer1.   

Abstract

OBJECTIVES: To investigate a potential outbreak of high-level azithromycin resistant (HL-AziR) gonococcal infections diagnosed in eight patients attending a sexual health clinic in Leeds, North England, between November 2014 and March 2015.
METHODS: Eight cases of infection with gonococci exhibiting azithromycin minimum inhibitory concentrations (MICs) ≥256 mg/L were identified from patients in Leeds as part of the routine service provided by the Sexually Transmitted Bacteria Reference Unit. All patient records were reviewed to collate epidemiological and clinical information including evaluation of patient management. Whole-genome sequencing (WGS) was performed on seven gonococcal isolates to determine Neisseria gonorrhoeae multiantigen sequence type (NG-MAST), WGS comparison and mutations in the 23S rRNA genes.
RESULTS: All patients were heterosexual (five male, three female) from a range of ethnic backgrounds and from the Leeds area. Three patients were linked by partner notification. All patients were infected at genital sites and two women had pharyngeal infection also. Six patients received the recommended first-line therapy for uncomplicated gonorrhoea, one was treated for pelvic inflammatory disease and one received spectinomycin followed later by ciprofloxacin. Test of cure was achieved in seven patients and confirmed successful eradication. All seven isolates sequenced were identical by NG-MAST and WGS comparison, and contained an A2143G mutation in all four 23S rRNA alleles.
CONCLUSIONS: Epidemiological and microbiological investigations confirm that an outbreak of a gonococcal strain showing HL-AziR is ongoing in the North of England. Every effort should be made to identify and curtail dissemination of this strain as it presents a significant threat to the current recommended front-line dual therapy. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Entities:  

Keywords:  ANTIMICROBIAL RESISTANCE; AZITHROMYCIN; BACTERIAL TYPING; NEISSERIA GONORRHOEA

Mesh:

Substances:

Year:  2015        PMID: 26601852     DOI: 10.1136/sextrans-2015-052312

Source DB:  PubMed          Journal:  Sex Transm Infect        ISSN: 1368-4973            Impact factor:   3.519


  44 in total

1.  Trends in antimicrobial susceptibility for azithromycin and ceftriaxone in Neisseria gonorrhoeae isolates in Amsterdam, the Netherlands, between 2012 and 2015.

Authors:  Carolien M Wind; Maarten F Schim van der Loeff; Alje P van Dam; Henry Jc de Vries; Jannie J van der Helm
Journal:  Euro Surveill       Date:  2017-01-05

2.  In Vitro Activity of Lefamulin against Sexually Transmitted Bacterial Pathogens.

Authors:  Susanne Paukner; Astrid Gruss; Jørgen Skov Jensen
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

Review 3.  Applications of genomics to slow the spread of multidrug-resistant Neisseria gonorrhoeae.

Authors:  Tatum D Mortimer; Yonatan H Grad
Journal:  Ann N Y Acad Sci       Date:  2018-06-06       Impact factor: 5.691

4.  A Case-Control Study of Molecular Epidemiology in Relation to Azithromycin Resistance in Neisseria gonorrhoeae Isolates Collected in Amsterdam, the Netherlands, between 2008 and 2015.

Authors:  Carolien M Wind; Sylvia M Bruisten; Maarten F Schim van der Loeff; Mirjam Dierdorp; Henry J C de Vries; Alje P van Dam
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

5.  Demographic and Epidemiological Characteristics Associated With Reduced Antimicrobial Susceptibility to Neisseria gonorrhoeae in the United States, Strengthening the US Response to Resistant Gonorrhea, 2018 to 2019.

Authors:  Karen E Gieseker; Emily R Learner; Kerry Mauk; Lindley A Barbee; Candice J McNeil; Gerald L Hasty; Jamie M Black; Kimberly Johnson; Trang Quyen Nguyen; Dhana Shrestha; Cau D Pham; Sancta St Cyr; Karen Schlanger; Robert D Kirkcaldy
Journal:  Sex Transm Dis       Date:  2021-12-01       Impact factor: 3.868

Review 6.  The frontiers of addressing antibiotic resistance in Neisseria gonorrhoeae.

Authors:  Daniel H F Rubin; Jonathan D C Ross; Yonatan H Grad
Journal:  Transl Res       Date:  2020-02-29       Impact factor: 7.012

7.  C4BP-IgM protein as a therapeutic approach to treat Neisseria gonorrhoeae infections.

Authors:  Serena Bettoni; Jutamas Shaughnessy; Karolina Maziarz; David Ermert; Sunita Gulati; Bo Zheng; Matthias Mörgelin; Susanne Jacobsson; Kristian Riesbeck; Magnus Unemo; Sanjay Ram; Anna M Blom
Journal:  JCI Insight       Date:  2019-12-05

8.  Cluster of Neisseria gonorrhoeae Isolates With High-level Azithromycin Resistance and Decreased Ceftriaxone Susceptibility, Hawaii, 2016.

Authors:  Alan R Katz; Alan Y Komeya; Robert D Kirkcaldy; A Christian Whelen; Olusegun O Soge; John R Papp; Ellen N Kersh; Glenn M Wasserman; Norman P O'Connor; Pamela S O'Brien; Douglas T Sato; Eloisa V Maningas; Gail Y Kunimoto; Juval E Tomas
Journal:  Clin Infect Dis       Date:  2017-09-15       Impact factor: 9.079

9.  Whole-genome sequencing to determine transmission of Neisseria gonorrhoeae: an observational study.

Authors:  Dilrini De Silva; Joanna Peters; John Paul; David W Eyre; Kevin Cole; Michelle J Cole; Fiona Cresswell; Gillian Dean; Jayshree Dave; Daniel Rh Thomas; Kirsty Foster; Alison Waldram; Daniel J Wilson; Xavier Didelot; Yonatan H Grad; Derrick W Crook; Tim Ea Peto; A Sarah Walker
Journal:  Lancet Infect Dis       Date:  2016-07-12       Impact factor: 25.071

10.  Evidence of Horizontal Gene Transfer of 50S Ribosomal Genes rplB, rplD, and rplY in Neisseria gonorrhoeae.

Authors:  Sheeba Santhini Manoharan-Basil; Jolein Gyonne Elise Laumen; Christophe Van Dijck; Tessa De Block; Irith De Baetselier; Chris Kenyon
Journal:  Front Microbiol       Date:  2021-06-10       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.